Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murray Baron

Showing results (241-250 of 281) with videos related to

Pageof 29
Sort By:
Rheumatology (Oxford, England)|June 19, 2023
Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature reviewLaura Ross, Nancy Maltez, Michael Hughes, et al.
Seminars in Arthritis and Rheumatism|October 12, 2023
Surgical management of digital ulcers in systemic sclerosis: A systematic literature reviewYossra A Suliman, Corrado Campochiaro, Michael Hughes, et al.
The Journal of Rheumatology|January 10, 2009
Symptoms of depression predict the trajectory of pain among patients with early inflammatory arthritis: a path analysis approach to assessing changeOrit Schieir, Brett D Thombs, Marie Hudson, et al.
Autoimmunity Reviews|February 25, 2026
Points to consider for reporting digital ulcers in systemic sclerosis interventional studies: An initiative from the world Scleroderma Foundation digital ulcer ad hoc committeeCorrado Campochiaro, Nancy Maltez, Yossra Suliman, et al.
Rheumatology (Oxford, England)|July 11, 2025
'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosisHana Sabanovic, John D Pauling, Murray Baron, et al.
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
Arthritis Care & Research|September 20, 2014
2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research GroupHebah Alhajeri, Marie Hudson, Marvin Fritzler, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Journal of Scleroderma and Related Disorders|August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc CommitteeNancy Maltez, Laura Ross, Murray Baron, et al.
Arthritis and Rheumatism|February 28, 2009
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trialLorinda Chung, Lee Shapiro, David Fiorentino, et al.
Pageof 29

Showing results (241-250 of 281) with videos related to

Sort By:
Pageof 29
Rheumatology (Oxford, England)|June 19, 2023
Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature reviewLaura Ross, Nancy Maltez, Michael Hughes, et al.
Seminars in Arthritis and Rheumatism|October 12, 2023
Surgical management of digital ulcers in systemic sclerosis: A systematic literature reviewYossra A Suliman, Corrado Campochiaro, Michael Hughes, et al.
The Journal of Rheumatology|January 10, 2009
Symptoms of depression predict the trajectory of pain among patients with early inflammatory arthritis: a path analysis approach to assessing changeOrit Schieir, Brett D Thombs, Marie Hudson, et al.
Autoimmunity Reviews|February 25, 2026
Points to consider for reporting digital ulcers in systemic sclerosis interventional studies: An initiative from the world Scleroderma Foundation digital ulcer ad hoc committeeCorrado Campochiaro, Nancy Maltez, Yossra Suliman, et al.
Rheumatology (Oxford, England)|July 11, 2025
'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosisHana Sabanovic, John D Pauling, Murray Baron, et al.
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
Arthritis Care & Research|September 20, 2014
2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research GroupHebah Alhajeri, Marie Hudson, Marvin Fritzler, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Journal of Scleroderma and Related Disorders|August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc CommitteeNancy Maltez, Laura Ross, Murray Baron, et al.
Arthritis and Rheumatism|February 28, 2009
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trialLorinda Chung, Lee Shapiro, David Fiorentino, et al.
Pageof 29